Replies to post #11791 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>IMO, this shows that while the street prices companies on past performance, prospective partners/buyers consider potential.<

The way I would put it is this: The stock market can be notoriously inefficient, but the market for buying and selling drugs and drug companies is generally quite efficient.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

[DragonBits]

It isn't so much the percentage gain as the fall of MEDE. It fell to over 1/2 sales (Revenue Per Share (ttm): 2.894), and last Q had just turned profitable.

So if GTC falls to 10 cents and gets bought out for 40 cents, it too will have a 400% gain.